Year
DEALS // DEV.
Country
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target
Lead Product(s) : Vibegron
Therapeutic Area : Urology
Study Phase : Approved FDF
Sponsor : Sumitomo
Deal Size : Undisclosed
Deal Type : Licensing Agreement
Details : KYORIN will grant Sumitomo Pharma the exclusive rights to develop, manufacture, and commercialize the therapeutic agent for OAB called Vibegron in in Taiwan and Other Asian Countries, and Sumitomo Pharma will develop, manufacture, and commercialize the C...
Product Name : Gemtesa
Product Type : Other Small Molecule
Upfront Cash : Undisclosed
June 03, 2023
Lead Product(s) : Vibegron
Therapeutic Area : Urology
Highest Development Status : Approved FDF
Sponsor : Sumitomo
Deal Size : Undisclosed
Deal Type : Licensing Agreement
Lead Product(s) : Vibegron
Therapeutic Area : Urology
Study Phase : Approved FDF
Sponsor : Eisai
Deal Size : Undisclosed
Deal Type : Licensing Agreement
KYORIN and Eisai Enter Into License Agreement Concerning the Development and Marketing of Vibegron
Details : Based on this agreement, Eisai will acquire exclusive development and marketing rights from Kyorin for the agent in the said four countries, and will be responsible for submitting a New Drug Application for the agent.
Product Name : Gemtesa
Product Type : Other Small Molecule
Upfront Cash : Undisclosed
March 31, 2021
Lead Product(s) : Vibegron
Therapeutic Area : Urology
Highest Development Status : Approved FDF
Sponsor : Eisai
Deal Size : Undisclosed
Deal Type : Licensing Agreement